Michael Brush
@mbrushstocks
Followers
4K
Following
3K
Media
547
Statuses
15K
MarketWatch columnist. Cabot. Stock letter: https://t.co/OURT9jAARf. đźš« consensus. Prior: NYT Business Economist Group MSN Columbia Biz Schl, Hopkins SAIS Italy.
Manhattan
Joined April 2020
Subscriber feedback: I’ve been bombarded with subscription offers -- Zack’s, MarketWatch, Barron’s, SeekingAlpha, Cramer and on and on. To me they are a waste of time. Thank you for your clear concise suggestions. Your presentation is simple, to the point and understandable.
10
5
78
One of the key themes right now. The striking dichotomy between robust consumer spending and soft labor data continues. - B of A
0
0
1
Market gurus writing poems to each other. Definite sign of a top? https://t.co/4P7ILbKQS7
Farzad, your verses are so clever, The accuracy of your TSLA forecasts never. You cling to your shares through thick and thin, Sometimes you should take profits and treasure the win. Valuation discipline is a guiding light. You give it no thought and disparage those who are
2
0
0
What's driving the sudden surge in small-cap stocks and IPOs? Why are large caps retreating? And should you now buy stocks based on potential interest from the U.S. government? We answered all those questions and more on today's Street Check https://t.co/ZRaeBdRk0j $INTC $LAC
cabotwealth.com
0
1
1
$MRUS now up 538% from where I suggested it in my stock letter Brush Up on Stocks, June 30, 2020, Full Issue, 8:00 pm EDT Merus (MRUS), Recent price: $14.80 MRUS has proprietary technology platforms called Biclonics and Triclonics that it thinks will help develop antibody
1
0
3
What the last quarter tells us about what's ahead for stocks and the economy. $DJIA $BKNG $DAL $BA $GE $GS $MS $GOOGL $MSFT $META $AMZN $NVDA $AVGO $CIEN $FIX $SPX $JPM $AMGN $LLY $RCL https://t.co/njrLrYjT06
marketwatch.com
Consumers will keep spending, AI and tech aren’t in a bubble, and there’s opportunity in Europe.
0
0
1
"we run" ... Does Adam run clinical trials now? @pawcio2009 @Varro_Analytics @BiotechObserver @biotech_hunter @matthewmillerai @JohnCendpts @ArmstrongDrew @Rajgillishere @JoeWaters_KW @Navaraaa @CaptainTight @chennak418 $IBB $XBI @SamFazeli8 @BrianSkorney @bio_clouseau
0
0
3
As predicted ... $MBX Biosciences Announces Proposed Public Offering Sep. 22, 2025 4:14 PM ET
0
0
1
And there it is... $MBX Biosciences Announces Proposed Public Offering Sep. 22, 2025 4:14 PM ET
0
0
0
$MBX last reiterated in my stock letter in the $5 range in April now up ~ 300% nice... Brush Up on Stocks, April 17, 2025, Full Issue Notable follow-on buying MBX where director buys $45K worth at $5.89 in the pummeled biotech sector Brush Up on Stocks, April 8, 2025,
0
0
1
$MBX last reiterated in my stock letter in the $5 range in April now up 133% nice... Brush Up on Stocks, April 17, 2025, Full Issue Notable follow-on buying MBX where director buys $45K worth at $5.89 in the pummeled biotech sector Brush Up on Stocks, April 8, 2025, Market
0
0
3
Bullish signal on $SMMT Jim Cramer on Summit Therapeutics: “We’re Going to Have to Move On”
0
1
3
Remember how Fed rate cutting was supposed bring down mortgage rates? (Note: Mortgage rates pegged to ten year)
0
0
1
$ETNB nice. Another one. Last suggested in my stock letter in Feb. Brush Up on Stocks, February 4, 2025, Update I, 1:45 pm EST 89bio (ETNB), Recent price: $10.40 $XBI $IBB @bradloncar @BiotechObserver @BiotechCH @pawcio2009 @Varro_Analytics @JohnCendpts @ArmstrongDrew
1
0
3
$ORKA nice, one of mine. $XBI $IBB Brush Up on Stocks, March 24, 2025, Full Issue, 1:23 pm EDT Oruka Therapeutics (ORKA), Recent price: $12.10 This is a very early-stage biotech company that is a...
0
0
0
Test it out below. Feedback very apprecaited https://t.co/81EqPOM30f
7
3
15
"We now estimate that the underlying pace of job growth has decelerated to about 25k jobs/month currently, below our estimate of the breakeven rate that would stabilize the unemployment rate. Other indicators of labor market tightness also suggest that the labor market has
2
0
4